Xenopus Resources: Transgenic, Inbred and Mutant Animals, Training Opportunities, and Web-Based Support
This reporter group also includes lines driven by ubiquitous promoters like CMV and human ubiquitin C. These are particularly useful for cut-and-paste, transplantation-based experiments to label and fate map regions of host embryos. The second group of reporter expression lines includes transgenics marking subcellular organelles (Supplementary Table S1B). These are highly useful for the study of molecular processes involved in cell function and are especially effective when utilized in the context of Xenopus egg extracts, the only cell-free system that permits full investigation of all DNA transactions related to cell cycle progression and DNA damage repair (Cross and Powers, 2009; Hoogenboom et al., 2017). Many of these lines have been generated by the Ueno lab and mark a diverse range of organelles including plasma membrane, Xla.Tg (CMV:RFP-CAAX)Ueno (RRID:EXRC_0075, NXR_0115), golgi bodies, Xla.Tg (CMV:Has.B4GALT1-eGFP)Ueno (RRID:EXRC_0077, NXR_0110), and microtubule plus ends, Xla.Tg (CMV:Has.MAPRE3-eGFP)Ueno (RRID:EXRC_0078, NXR_0109) (Takagi et al., 2013). Lines generated by other labs, as well as by the stock centers themselves, that label other organelles are also available. The third group of reporter lines are those that serve as indicators of signaling activity (Supplementary Table S1C). These include Wnt signaling reporter lines generated by the Vleminckx lab in both X. laevis and X. tropicalis (Tran et al., 2010), an apoptosis sensor (Kominami et al., 2006), a ...
No abstract available
Orthopedic indications collectively represent a large clinical and economic burden, especially given the aging world population. To meet this area of unmet need, a wave of regenerative medicine therapies, including stem cells and other cell-based therapies, is currently in clinical development and anticipated to inundate the global market over the next few years. Although intended to be transformative, orthopedic cell therapies face several practical opportunities and challenges. Such therapies could reduce the health care burden, in part by replacing traditional drug therapies and highly-invasive surgical interventions wi...
Conclusions: MSC therapies in the treatment of knee OA are safe and have shown promising results but the available studies are limited. At this time, no definitive recommendations can be made regarding which MSC source to use. Allogeneic MSCs offer theoretical advantages over autologous MSCs, especially in ease of use and consistency of product, but there are concerns regarding cell viability and vitality, as well as the body’s response to nonautologous products. Future clinical trials should focus on randomized head-to-head comparisons of MSC sources as well as the use of multiple injections for patients with knee OA.
Low back pain and neck pain are the first and fourth leading causes, respectively, of years lived with disability. The treatment of intervertebral disk degeneration remains a significant challenge. While there are still many obstacles to overcome, the use of stem cells for the treatment of disk degeneration has emerged as one of the most promising and exciting techniques to restore the structure and function of the degenerated disk. The use of stem cells in treating intervertebral disk disease as well as the obstacles that remain are reviewed here in an evidence-based manner.
Osteosarcoma (OS) is the most common primary bone malignancy and is a leading cause of cancer-related death in children and young adults. Combination chemotherapy developed 3 decades ago significantly improved long-term survival compared to surgery alone. However, despite notable tumor cytoreduction and remission, the 5-year survival rate has remained static at ∼70% since, and the surviving patients have high chemoresistance with sustained risk of recurrent OS that has propensity to metastasize. After metastasis, the 5-year survival rate is abysmally low (∼10% to 20%). Emerging new evidence has revealed that within...
Conclusion. Our findings indicate that MSC homing enhances the survival and regenerative capability of IVD cells, which may be mediated by intercellular communication. MSC homing could represent a potential treatment strategy to prevent the onset of the degenerative cascade in IVDs at risk such as IVDs adjacent to a fused segment or IVDs after herniation. Level of Evidence: N/A
Conclusion. rs11190870 in LBX1, a strong susceptibility SNP for AIS, may also be a susceptibility SNP for ASD. Thus, ASD and AIS may share a common genetic background. Level of Evidence: 4
Conclusion. Anxiety and mood are potentially modifiable risk factors that have the greatest impact on pre- and postoperative pain. These results can be used to identify higher-risk patients and develop preoperative therapeutic protocols to improve postoperative outcomes. Level of Evidence: 3
CONCLUSIONS: In this review, biological and chemical knowledge of melatonin, its experimental effects, and the clinical impact on patients with neurological disorders were described. According to all of the beneficial results obtained from experimental and clinical trials, melatonin may have a prophylactic and therapeutic effect on neurological diseases. Strong collaboration between neurologists and health service policy makers is needed to encourage use of melatonin in the patients suffering from neurological diseases. Melatonin may be the solution we have been looking for. PMID: 31718830 [PubMed - as supplied by publisher]
Authors: Philip T, Karjalainen S, De Lorenzo F, Apostolidis K, Lombardo C, Nilbert M, Lacombe D, Poortmans P, Albreht T, Kearns P, Vassal G Abstract The European cancer burden is growing rapidly, with an estimated 2 million deaths a year according to the latest research. As almost half of cancers are diagnosed after the age of 65, and considering the aging European population, a tidal wave of cancer cases will sweep across Europe within the coming decades. Without major action, the additional number of annual cancer cases is expected to rise from 4.2 million to 5.2 million by 2040. If we are to reach plateauing num...
More News: Academia | Allergy & Immunology | Biochemistry | Biology | Brain | Burns | Calcium | Cancer | Cancer & Oncology | Cardiology | Child Development | Children | Conferences | Cytology | Databases & Libraries | Depression | Doxycycline | Education | Environmental Health | Epilepsy | Eye Cancers | Fish | France Health | Fruit | Funding | Gastroenterology | Gastroschisis Repair | Genetics | Graduation | Grants | Heart | Heart Disease | Heart Transplant | Hormones | Infectious Diseases | Japan Health | Kidney Transplant | Kidney Transplantation | Laboratory Medicine | Learning | Legislation | Microbiology | Mitochondrial Disease | Molecular Biology | Nanotechnology | Neurology | Neuroscience | New Zealand Health | Nigeria Health | Orthopaedics | Physiology | Pregnancy | Reproduction Medicine | Research | Retinitis Pigmentosa | Retinoblastoma | Science | Stem Cell Therapy | Stem Cells | Students | Study | Teaching | Tetracycline | Thyroid | Thyroid Cancer | Training | Transplants | UK Health | Universities & Medical Training | Urology & Nephrology | USA Health | Websites | Workshops | Yale | Zinc | Zoology